Skip to main content
. 2021 May 21;47(6):641–652. doi: 10.1007/s00134-021-06416-z

Table 2.

Primary, sub-group, secondary, and sensitivity outcome data for included trials

Outcome References Intervention group Control group Conventional effect estimate
(95% CI)
Overall effect I2 (%)
Overall mortality [1921, 2328] 821/3358 (24.4%) 909/3135 (29%) 0.87 (0.74–1.01) Z = 1.82 p = 0.07 10
ICU patient mortality [19, 21, 23] 254/732 (34.7%) 297/750 (39.6%) 0.84 (0.65–1.10) Z = 1.27 p = 0.20 24
Disease progression
 Mechanical ventilation [20, 21, 2326, 28] 152/1742 (8.7%) 152/1454 (10.5%) 0.70 (0.54–0.89) Z = 2.86 p = 0.004 0
 ICU admission [20, 23, 26, 28] 118/338 (34.9%) 117/282 (41.5%) 0.73 (0.38–1.39) Z = 0.96 p = 0.34 60
 Composite outcome [1821, 2327] 808/2796 (28.9%) 943/2577 (36.6%) 0.72 (0.59–0.89) Z = 3.14 p = 0.002 26
Sensitivity analysis
 Combined IL-6 antagonists mortality [1928] 861/3738 (23%) 916/3219 (28.5%) 0.86 (0.74–1.01) Z = 1.85 p = 0.06 10
 Sarilumab mortality [19, 23] 40/377 (10.6%) 149/481 (31%) 0.72 (0.35–1.51) Z = 0.86 p = 0.39 42

ICU intensive-care unit